-

AmerisourceBergen Announces Common Share Repurchase From Walgreens Boots Alliance

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Corporation (NYSE: ABC) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance’s entry into certain variable pre-paid forward transactions executed in reliance on Rule 144 under the Securities Act of 1933, as amended.

AmerisourceBergen intends to repurchase shares from Walgreens Boots Alliance at the per share price equal to the price in the Rule 144 transaction. The concurrent share repurchase will be made under AmerisourceBergen’s share repurchase program and the repurchased shares will be held in treasury.

About AmerisourceBergen

AmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500 with more than $200 billion in annual revenue.

Contacts

Investors:
Bennett S. Murphy
Senior Vice President, Head of Investor Relations & Treasury
610-727-3693
bmurphy@amerisourcebergen.com

AmerisourceBergen Corporation

NYSE:ABC

Release Versions

Contacts

Investors:
Bennett S. Murphy
Senior Vice President, Head of Investor Relations & Treasury
610-727-3693
bmurphy@amerisourcebergen.com

More News From AmerisourceBergen Corporation

Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2025 fourth quarter ended September 30, 2025, revenue increased 5.9 percent to $83.7 billion. Revenue increased 9.3 percent to $321.3 billion for fiscal year 2025. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $(1.75) for the September quarter of fiscal 2025, compared to $0.02 in the prior year quarter. Adjusted diluted EPS, which is a...

Cencora Announces Date and Time for Fourth Quarter Fiscal 2025 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2025 on Wednesday, November 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 5, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President &...

Cencora Appoints Mark Durcan as Chairman of Its Board of Directors

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has appointed Lead Independent Director D. Mark Durcan as Chairman of the Board of Directors, effective October 1, 2025. Mr. Durcan will succeed Steven H. Collis, who has served as Cencora’s Chairman since 2016 and previously served as Cencora’s Chief Executive Officer from 2011 until 2024. As previously disclosed, Mr. Collis was elected to serve as Executive Chairman of the Board effective...
Back to Newsroom